Neonatal Medicine

The Korean Society of Neonatology (대한신생아학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect on Pulmonary Indices of Surfactant Therapy for Meconium Aspiration Syndrome: Systematic Review and Meta-analysis

태변흡인증후군에서 폐표면활성제 사용이 호흡기지표에 미치는 영향에 대한 체계적 문헌고찰과 메타분석

  • Choi, Hyun-Jin (Department of Preventive Medicine, Seoul National University College of Medicine) ;
  • Hahn, Seo-Kyung (Department of Medicine, Seoul National University College of Medicine) ;
  • Lee, Soon-Min (Department of Pediatrics, College of Medicine, Yonsei University) ;
  • Kim, Han-Suk (Department of Pediatrics, Seoul National University College of Medicine) ;
  • Bae, Chong-Woo (Department of Pediatrics, Kyung Hee University School of Medicine)
  • 최현진 (서울대학교 의과대학 예방의학교실) ;
  • 한서경 (서울대학교 의과대학 의학과) ;
  • 이순민 (연세대학교 의과대학 소아과학교실) ;
  • 김한석 (서울대학교 의과대학 소아과학교실) ;
  • 배종우 (경희대학교 의과대학 소아과학교실)
  • Published : 2011.11.30
⟨ Previous Next ⟩

Abstract

Purpose: Surfactants have been used to improve oxygenation for infants with meconium aspiration syndrome (MAS). We evaluated the change of pulmonary indices after surfactant therapy for MAS through a systematic meta-analysis. Methods: Relevant randomized controlled studies (RCTs) were identified by database searches in MEDLINE, EMBASE, and CENTRAL, up to June 2011, and by additional hand searches. Data were extracted regarding pulmonary indices, such as the oxygen index and arterial alveolar oxygen gradient. Meta-analyses were separately conducted for the studies of surfactant lavage therapy and surfactant bolus therapy. The risk of bias was assessed, and clinical as well as statistical heterogeneities were also investigated. Results: Two RCTs for bolus surfactant therapy and two RCTs for surfactant lavage therapy were identified. The oxygenation index results were heterogeneous between the two studies in which bolus surfactant therapy was given, while a/A $PO_2$ showed significantly better results in the treatment group over time after use of surfactant (12 hours: WMD 0.08, 95% CI 0.04-0.12; 24 hours: WMD 0.17, 95% CI 0.06-0.28). For surfactant lavage therapy, both studies consistently suggested an interventional benefit in terms of the pulmonary indices although it did not reach statistical significance. Conclusion: Surfactant therapy appeared to improve oxygenation of infants with MAS. Since a limited number of RCTs are available in the current literature and those studies were also clinically heterogeneous in terms of illness severity and the method of surfactant use, further research is needed to gather evidence to support surfactant therapy in MAS.

목적: 최근 폐표면활성제는 태변흡인증후군 환자에서 호흡곤란을 호전시키기 위한 치료 중 하나로 사용되고 있다. 본 연구에서는 태변흡인증후군에서 폐표면활성제가 치료결과로서 호흡기지표에 미치는 영향을 살펴보았다. 방법: MEDLINE, EMBASE, CENTRAL 등의 주요 데이터베이스 및 초록 등을 검색하여 2011년 6월까지 보고된 관련 무작위 배정연구를 선별하였다. OI 또는 a/A $PO_2$와 같은 호흡기 지표를 포함한 자료를 추출하여 폐표면활성제 보충요법과 폐표면활성제 세정요법 각각에 대해 메타분석을 수행하였다. 비뚤림 위험 및 임상적, 통계적 이질성을 평가하였다. 결과: 두 건의 폐표면활성제 보충요법 연구와 두 건의 폐표면 활성제 세정요법 연구가 분석에 포함되었다. 폐표면활성제 보충요법의 경우 OI에서는 두 연구 결과 사이의 이질성이 큰 반면, a/A $PO_2$에서는 보충요법 후 시간이 경과할 수록 군 간의 차이가 유의하게 나타났다(12시간째 WMD 0.08, 95% CI 0.04, 0.12; 24시간째 WMD 0.17, 95% CI 0.06, 0.28). 폐표면활성제 세정요법의 경우 통합하여 분석하였을 때 치료군이 대조군에 비해 임상 경과가 좋은 경향을 보였으나 통계적인 유의성은 확보하지는 못하였다. 결론: 태변흡인증후군에서 폐표면활성제 사용은 임상경과를 호전시키는 것으로 보인다. 기존의 연구수가 제한되어 있고 대상환자의 중증도 및 폐표면활성제 투여방법 또한 서로 다르므로 추가적인 연구를 통한 보충적인 근거가 도움이 될 것이다.

Keywords

References

  1. Kim DY, Bae SY, Joo JW, Kim MJ, Song ES, Choi YY. Frequency and clinical outcome of the respiratory tract disease in full-term infant. J Korean Soc Neonatol 2007;14:199-205.
  2. Davey AM, Becker JD, Davis JM. Meconium aspiration syndrome: physiological and inflammatory changes in a newborn piglet model. Pediatr Pulmonol 1993;16:101-8. https://doi.org/10.1002/ppul.1950160205
  3. Bae CW, Takahashi A, Chida S, Sasaki M. Morphology and function of pulmonary surfactant inhibited by meconium. Pediatr Res 1998;44:187-91. https://doi.org/10.1203/00006450-199808000-00008
  4. Cleary GM, Wiswell TE. Meconium-stained amniotic fluid and the meconium aspiration syndrome. An update. Pediatr Clin North Am 1998;45:511-29. https://doi.org/10.1016/S0031-3955(05)70025-0
  5. Dargaville PA, Mills JF. Surfactant therapy for meconium aspiration syndrome: current status. Drugs 2005;65:2569-91. https://doi.org/10.2165/00003495-200565180-00003
  6. El Shahed AI, Dargaville P, Ohlsson A, Soll RF. Surfactant for meconium aspiration syndrome in full term/near term infants. Cochrane Database Syst Rev 2007:(3):CD002054.
  7. Choi HJ, Hahn S, Lee J, Park BJ, Lee SM, Kim HS, et al. Surfactant lavage therapy for meconium aspiration syndrome: a systematic review and meta-analysis. Neonatology 2011;101:183-191.
  8. Trachsel D, McCrindle BW, Nakagawa S, Bohn D. Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure. Am J Respir Crit Care Med 2005;172:206-11. https://doi.org/10.1164/rccm.200405-625OC
  9. Jeon JH, Namgung R, Park MS, Park KI, Lee C. Oxygenation index as a respiratory parameter of respiratory distress syndrome in preterm infants. Korean J Pediatr 2008;51:145-9. https://doi.org/10.3345/kjp.2008.51.2.145
  10. Hall RT. Indications for surfactant therapy--the aAPO2 coming of age. Pediatrics 1999;103:E25.
  11. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions Version 5.0.2 (updated September 2009). The Cochrane Collaboration, 2009. Available from: http://www.mrc-bsu.cam.ac.uk/cochrane/handbook502/.
  12. Chinese Collaborative Study Group for Neonatal Respiratory Diseases. Treatment of severe meconium aspiration syndrome with porcine surfactant: a multicentre, randomized, controlled trial. Acta Paediatr 2005;94:896-902. https://doi.org/10.1080/08035250510028344
  13. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndrome. Pediatrics 1996;97:48- 52.
  14. Wiswell TE, Knight GR, Finer NN, Donn SM, Desai H, Walsh WF, et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002;109:1081-7. https://doi.org/10.1542/peds.109.6.1081
  15. Dargaville PA, Copnell B, Mills JF, Haron I, Lee JK, Tingay DG, et al. Randomized controlled trial of lung lavage with dilute surfactant for meconium aspiration syndrome. J Pediatr 2011;158:383-9. https://doi.org/10.1016/j.jpeds.2010.08.044
  16. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH, et al. Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure.J Pediatr 1998;132:40-7. https://doi.org/10.1016/S0022-3476(98)70482-2
  17. Cleary GM, Antunes MJ, Ciesielka DA, Higgins ST, Spitzer AR, Chander A. Exudative lung injury is associated with decreased levels of surfactant proteins in a rat model of meconium aspiration. Pediatrics 1997;100:998-1003. https://doi.org/10.1542/peds.100.6.998
  18. Fuchimukai T, Fujiwara T, Takahashi A, Enhorning G. Artificial pulmonary surfactant inhibited by proteins. J Appl Physiol 1987;62:429-37. https://doi.org/10.1063/1.339816
  19. Roberts JD Jr, Fineman JR, Morin FC 3rd, Shaul PW, Rimar S, Schreiber MD, et al. Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. N Engl J Med 1997;336:605-10. https://doi.org/10.1056/NEJM199702273360902
  20. Park HK, Lim JW, Jun NL, Kim EA, Kim KS, Pi SY. Comparison of treatment outcomes in persistent pulmonary hypertension of the newborn. J Korean Soc Neonatol 2003;10:29-38.